Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in CMV-Seropositive Kidney Transplant Recipients Who Received Antilymphocyte Induction Therapy

NCT02439957 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT02439957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02439957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in CMV-Seropositive Kidney Transplant Recipients Who Received Antilymphocyte Induction Therapy
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2015
Completion date
July 31, 2016
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus disease, kidney transplant infection